USANA Health Sciences Files 8-K on Financial Condition & Operations

TL;DR

**USANA just dropped an 8-K on financials, get ready for an update on their performance.**

AI Summary

USANA Health Sciences, Inc. filed an 8-K on February 6, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the health and trajectory of the business. For shareholders or potential buyers, this matters because it offers current financial insights that could influence stock valuation and future investment decisions.

Why It Matters

This filing provides investors with the latest financial health update for USANA Health Sciences, directly impacting their assessment of the company's performance and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate new risks.

Analyst Insight

A smart investor would review the full details of the 'Results of Operations and Financial Condition' once they become available to assess USANA's recent performance and adjust their investment thesis accordingly.

Key Numbers

• 001-35024 — Commission File Number (identifies USANA's filings with the SEC)
• 87-0500306 — IRS Employer Identification Number (identifies USANA for tax purposes)

Key Players & Entities

• USANA HEALTH SCIENCES, INC. (company) — the registrant filing the 8-K
• New York Stock Exchange (company) — where USANA's Common Stock is registered
• 001-35024 (dollar_amount) — Commission File No.
• 87-0500306 (dollar_amount) — IRS Employer Identification No.
• February 6, 2024 (date) — Date of Report (Date of Earliest Event Reported)

Forward-Looking Statements

• USANA Health Sciences will likely release detailed financial statements soon. (USANA HEALTH SCIENCES, INC.) — high confidence, target: 2024-03-31

FAQ

From the Filing

0001157523-24-000176.txt : 20240206 0001157523-24-000176.hdr.sgml : 20240206 20240206161529 ACCESSION NUMBER: 0001157523-24-000176 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240206 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 24600462 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 a53892955.htm USANA HEALTH SCIENCES, INC. 8-K false 0000896264 0000896264 2024-02-06 2024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________   FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): February 6, 2024   USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024   87-0500306 (Commission File No.)   (IRS Employer Identification No.)   3838 West Parkway Boulevard Salt Lake City , Utah 84120 (Address of principal executive offices, Zip Code)  Registrant's telephone number, including area code: ( 801 ) 954-7100   Check the appropriate box below if the Form 8-K fi ling is intended to simultaneously satisfy the fi ling obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 per value per share   USNA   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as de fi ned in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( § 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised fi nancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02   Results of Operations and Financial Condition. On February 6, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 30, 2023.  The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access info